Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk of nephrotoxicity from intravenous nonionic iodinated contrast media
2012-004742-16Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iomeprol, iopamidol, iobitridol and iopromide in contrast-induced nephropathy (CIN), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Total incidence of contrast-induced nephropathy (CIN). Started Oct 2012; status: active.
02
Drugs
iomeproliopamidoliobitridoliopromide
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on 2012-004742-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004742-16.